drugset / Trial / NCT01221636

Pharmacokinetic Study to Compare the Blood Levels of Low vs High Metal Manufacture of Abatacept

NCT01221636

Phase 1 Withdrawn Bristol-Myers Squibb
RandomizedParallel-groupOpen-label

Summary

The purpose of this study is to determine whether the blood levels of abatacept drug product manufactured using High Metals and using Low Metals are comparable in healthy subjects.

Timeline

Start
2010-10
Primary completion
2011-02
Completion
2011-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Abatacept Other / unclassified 750 mg Intravenous

Indications